drugset / Trial / NCT00432315
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: • To assess the response rate to induction therapy with docetaxel/CDDP. Secondary objectives: To assess * Resectability after induction therapy * Time to progression * Overall survival * Safety profile * Quality of Life
Timeline
- Start
- 2001-05
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |